Continued support of existing investors will fund commercialization efforts, product launch later this year BOULDER, Colo., April 4, 2019-- Inscripta, a leading gene editing technology company, today announced that it has increased its previously announced Series C financing with an additional $20 million from existing investors. The new funding adds to the $85.5 million financing Inscripta announced in 2018, bringing the total raised for the round to $105.5 million. “I would like to thank our investors for this expansion of our Series C round and their continued support and enthusiasm,” said Kevin Ness, CEO of Inscripta.